ReviewMedicinal research reviews2025
Progress in Molecular Imprinting-From Inhibition of Enzymatic Activity to Regulation of Cellular Pathways.
Review in Medicinal research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecularly Imprinted Polymer Nanoparticles for Reducing Herpes Simplex Virus Type 2 Infection.ACS omega · 2026Article
- [Research progress of molecular imprinting technology in the field of disease diagnosis and therapy].Se pu = Chinese journal of chromatography · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imprinting is a very powerful tool in life science. The research areas benefiting from a wide range of capabilities of molecularly imprinted polymeric nanoparticles (nanoMIPs) include sample preparation, extraction, sensing/detection, diagnostics, and drug delivery. Recently, a new member of this family-therapy/control of cellular reactions-has arrived. Within this newest field, so far, the design and synthesis of very selective enzymatic inhibitors/activators have been described. Since enzymes act as catalysts of biochemical reactions, nanoMIPs pose enormous potential in managing biological processes. Furthermore, in recent years, articles focused on influencing cellular pathways by either interaction with cell surface receptors or by inactivation of signal molecules have begun to appear. This strategy opens a new perspective for nanoMIPs application-as selective, inexpensive, and stable therapeutics. However, there are still a lot of questions to be answered and many issues that must be addressed before the practical implementation of nanoMIPs in the therapeutic area. Among the main challenges belong safety, biodegradability, biodistribution, and clearance of nanoMIPs from the organism as well as their reproducible large-scale production in accordance with quality control. This review aims to summarize the progress in nanoMIPs development enabling them to overcome main issues and increasing their competitiveness in the therapeutic area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.